OA12653A - Oral antidiabetic agents. - Google Patents

Oral antidiabetic agents. Download PDF

Info

Publication number
OA12653A
OA12653A OA1200400053A OA1200400053A OA12653A OA 12653 A OA12653 A OA 12653A OA 1200400053 A OA1200400053 A OA 1200400053A OA 1200400053 A OA1200400053 A OA 1200400053A OA 12653 A OA12653 A OA 12653A
Authority
OA
OAPI
Prior art keywords
phenyl
methyl
propionic acid
oxazol
ethoxy
Prior art date
Application number
OA1200400053A
Other languages
English (en)
Inventor
Christopher Franklin Bigge
Alexander James Bridges
Agustin Casimoro-Garcia
Stephen Alan Fakhoury
Helen Tsenwhei Lee
Jessica Elizabeth Reed
Robert Philipp Schaum
Kevin Matthew Schlosser
Karen Elaine Sexton
Hairong Zhou
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of OA12653A publication Critical patent/OA12653A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
OA1200400053A 2001-08-29 2002-07-15 Oral antidiabetic agents. OA12653A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31572801P 2001-08-29 2001-08-29

Publications (1)

Publication Number Publication Date
OA12653A true OA12653A (en) 2006-06-16

Family

ID=23225787

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200400053A OA12653A (en) 2001-08-29 2002-07-15 Oral antidiabetic agents.

Country Status (35)

Country Link
EP (2) EP1423363B1 (cs)
JP (1) JP2005504778A (cs)
KR (1) KR20040044515A (cs)
CN (1) CN1558897A (cs)
AP (1) AP2002002616A0 (cs)
AR (1) AR036301A1 (cs)
AT (1) ATE323674T1 (cs)
BG (1) BG108597A (cs)
BR (1) BR0212069A (cs)
CA (1) CA2458621A1 (cs)
CZ (1) CZ2004272A3 (cs)
DE (1) DE60210784T2 (cs)
EA (1) EA200400140A1 (cs)
EC (1) ECSP044999A (cs)
EE (1) EE200400075A (cs)
ES (1) ES2260456T3 (cs)
GT (1) GT200200175A (cs)
HN (1) HN2002000242A (cs)
HR (1) HRP20040164A2 (cs)
HU (1) HUP0401620A2 (cs)
IL (1) IL159886A0 (cs)
IS (1) IS7114A (cs)
MA (1) MA27135A1 (cs)
MX (1) MXPA04001968A (cs)
NO (1) NO20040881L (cs)
OA (1) OA12653A (cs)
PA (1) PA8553701A1 (cs)
PE (1) PE20030563A1 (cs)
PL (1) PL369569A1 (cs)
SK (1) SK1182004A3 (cs)
SV (1) SV2003001213A (cs)
TN (1) TNSN04038A1 (cs)
UY (1) UY27424A1 (cs)
WO (1) WO2003018553A1 (cs)
ZA (1) ZA200400374B (cs)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003203170A1 (en) * 2002-01-17 2003-07-30 Takeda Chemical Industries, Ltd. Nitrogenous heterocyclic compounds, process for preparation of the same and use thereof
PA8594401A1 (es) * 2003-02-21 2004-09-16 Pfizer Acidos carboxilicos de heteroarilo condensado como agonista del ppar
WO2004098498A2 (en) * 2003-04-28 2004-11-18 Bayer Pharmaceuticals Corporation Indole acetic acid derivatives and their use as pharmaceutical agents
EP1641788A1 (en) * 2003-06-27 2006-04-05 Warner-Lambert Company LLC Preparation of n2-alkylated 1,2,3-triazoles
BRPI0412236A (pt) * 2003-07-02 2006-09-12 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas ppar(delta) e/ou ppar(alfa), e utilização desses compostos
BRPI0412684A (pt) * 2003-07-17 2006-10-03 Plexxinko Inc compostos ppar-ativos
AU2004291259A1 (en) * 2003-11-05 2005-06-02 F. Hoffmann-La Roche Ag Heteroaryl derivatives as PPAR activators
WO2005056522A2 (en) 2003-12-04 2005-06-23 National Health Research Institutes Indole compounds
ATE359284T1 (de) * 2003-12-11 2007-05-15 Galderma Res & Dev Neue verbindungen, bei denen es sich um modulatoren von rezeptoren vom ppar-typ handelt, und deren verwendung in kosmetischen oder pharmazeutischen zusammensetzungen
FR2863610B1 (fr) * 2003-12-11 2006-01-20 Galderma Res & Dev NOUVEAUX COMPOSES MODULATEURS DES RECEPTEURS DE TYPE PPARs ET LEUR UTILISATION DANS DES COMPOSITIONS COSMETIQUES OU PHARMACEUTIQUES
US7456218B2 (en) 2003-12-25 2008-11-25 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl) propanoic acid derivatives
RU2375357C2 (ru) * 2004-03-09 2009-12-10 Ф.Хоффманн-Ля Рош Аг Производные пиразолилиндолила в качестве активаторов ppar
US7405236B2 (en) * 2004-08-16 2008-07-29 Hoffman-La Roche Inc. Indole derivatives comprising an acetylene group
TW200724138A (en) * 2005-03-29 2007-07-01 Sk Corp Substituted carboxylic acid derivatives for the treatment of diabetes and lipid disorders, their preparation and use
EP2014652B1 (en) * 2006-04-18 2014-08-06 Nippon Chemiphar Co., Ltd. Activating agent for peroxisome proliferator activated receptor
AU2013202514B2 (en) * 2006-04-18 2015-09-17 Nippon Chemiphar Co., Ltd. Activating agent for peroxisome proliferator activated receptor delta
PE20080188A1 (es) * 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
MX2010011252A (es) 2008-04-15 2010-11-30 Nippon Chemiphar Co Activador para el receptor activado por el proliferador de peroxisoma.
FR2976943B1 (fr) * 2011-06-23 2013-07-12 Metabolys Derives de piperazine, leurs procedes de preparation et leurs utilisations dans le traitement de l'insulinoresistance
FR2976942B1 (fr) 2011-06-23 2013-07-12 Metabolys Derives de piperazine, leurs procedes de preparation et leurs utilisations dans le traitement de l'insulinoresistance
WO2013139341A1 (en) * 2012-03-20 2013-09-26 Syddansk Universitet Gpr120 receptor modulators
WO2013185766A1 (en) * 2012-06-15 2013-12-19 Syddansk Universitet Gpr120 receptor modulators
WO2025141118A1 (en) * 2023-12-27 2025-07-03 Institut National de la Santé et de la Recherche Médicale Arylalkyloxyindole compounds and derivatives and their use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69941777D1 (de) * 1998-03-10 2010-01-21 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
CN1208326C (zh) * 1998-04-23 2005-06-29 雷迪实验室有限公司 杂环化合物及其在医药方面的应用、其制备方法及含有它们的药物组合物
WO2000023425A1 (en) * 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
US6274608B1 (en) * 1999-04-20 2001-08-14 Novo Nordisk A/S Compounds, their preparation and use
EP1175412A1 (en) * 1999-04-28 2002-01-30 Dr. Reddy's Research Foundation Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents
EP1210345B1 (en) * 1999-09-08 2004-03-03 Glaxo Group Limited Oxazole ppar antagonists

Also Published As

Publication number Publication date
MXPA04001968A (es) 2004-06-07
EE200400075A (et) 2004-08-16
SV2003001213A (es) 2003-03-18
DE60210784D1 (de) 2006-05-24
ATE323674T1 (de) 2006-05-15
AR036301A1 (es) 2004-08-25
HN2002000242A (es) 2002-12-12
EP1423363B1 (en) 2006-04-19
EA200400140A1 (ru) 2004-08-26
MA27135A1 (fr) 2005-01-03
TNSN04038A1 (fr) 2006-06-01
KR20040044515A (ko) 2004-05-28
PL369569A1 (en) 2005-05-02
WO2003018553A1 (en) 2003-03-06
HUP0401620A2 (hu) 2004-11-29
CA2458621A1 (en) 2003-03-06
GT200200175A (es) 2003-05-23
SK1182004A3 (sk) 2005-03-04
NO20040881L (no) 2004-04-19
EP1577305A1 (en) 2005-09-21
HRP20040164A2 (en) 2004-10-31
WO2003018553A8 (en) 2004-04-08
CN1558897A (zh) 2004-12-29
DE60210784T2 (de) 2006-11-02
BR0212069A (pt) 2004-07-20
JP2005504778A (ja) 2005-02-17
AP2002002616A0 (en) 2002-09-30
CZ2004272A3 (cs) 2005-02-16
PE20030563A1 (es) 2003-06-23
PA8553701A1 (es) 2003-07-28
BG108597A (bg) 2005-03-31
EP1423363A1 (en) 2004-06-02
ES2260456T3 (es) 2006-11-01
ZA200400374B (en) 2005-03-30
IL159886A0 (en) 2004-06-20
IS7114A (is) 2004-01-15
UY27424A1 (es) 2003-03-31
ECSP044999A (es) 2004-04-28

Similar Documents

Publication Publication Date Title
CA2458621A1 (en) Oral antidiabetic agents
CN111138301B (zh) 联苯类化合物、其中间体、制备方法、药物组合物及应用
RU2650506C2 (ru) Агонист рецептора gpr40, способы его получения и фармацевтические композиции, содержащие его в качестве активного ингредиента
WO2004106276A1 (ja) 縮合環化合物
US20030087902A1 (en) Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-gamma binding agents
CA2471885A1 (en) 4-sulfide / sulfoxide / sulfonyl-1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor
EA027113B1 (ru) Регуляторы пути комплемента и их применение
EA016475B1 (ru) Азольные соединения для применения в качестве fxr модуляторов
AU2005233160A1 (en) CETP inhibitors
OA11980A (en) Indazole compounds and pharmaceutical compositionsfor inhibiting protein kinases, and methods for t heir use.
WO2003084916A2 (en) Compounds that modulate ppar activity and methods for their preparation
KR20050010507A (ko) 신규 치환 인돌
KR20070044440A (ko) 이종고리-치환된 환식 우레아 유도체, 그의 제조 방법 및그의 키나아제 억제제로서의 제약학적 용도
JP2005501856A5 (cs)
HUP0300857A2 (hu) Peroxiszóma proliferátor aktivált agonisták
US20030171377A1 (en) Antidiabetic agents
IL294092A (en) 4-phenyl-n-(phenyl)thiazol-2-amine derivatives and related compounds as aryl hydrocarbon receptor (ahr) agonists for the treatment of e.g. angiogenesis implicated or inflammatory disorders
CA2521135A1 (en) N-containing heteroaromatic compounds as modulators of ppars and methods of treating metabolic disorders
CA2523245C (en) Indole acetic acid derivatives and their use as pharmaceutical agents
JP2003292439A (ja) 新規ピロール誘導体からなるｐｐａｒ活性化剤
US6716842B2 (en) Antidiabetic agents
AU2002317434A1 (en) Oral antidiabetic agents
JP2002322163A (ja) ピペラジン誘導体
US6696474B2 (en) Antidiabetic agents
JP2006036730A (ja) 新規ピロール誘導体